Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) have earned an average recommendation of “Buy” from the twelve ratings firms that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell rating and nine have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $34.00.

Several equities analysts have commented on the stock. Cowen and Company reissued an “outperform” rating and issued a $45.00 price target on shares of Coherus BioSciences in a research report on Friday, September 8th. Maxim Group reissued a “buy” rating and issued a $20.00 price target (down previously from $40.00) on shares of Coherus BioSciences in a research report on Friday, September 8th. Zacks Investment Research cut shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. Credit Suisse Group reissued an “outperform” rating and issued a $17.00 price target (down previously from $24.00) on shares of Coherus BioSciences in a research report on Wednesday, September 27th. Finally, J P Morgan Chase & Co reissued an “overweight” rating and issued a $25.00 price target (down previously from $32.00) on shares of Coherus BioSciences in a research report on Tuesday, August 8th.

ILLEGAL ACTIVITY WARNING: “Coherus BioSciences, Inc. (CHRS) Given Consensus Rating of “Buy” by Brokerages” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/12/coherus-biosciences-inc-chrs-given-consensus-rating-of-buy-by-brokerages.html.

Shares of Coherus BioSciences (NASDAQ CHRS) traded up 0.70% during trading on Thursday, reaching $14.40. 527,760 shares of the company were exchanged. The firm has a 50-day moving average price of $13.50 and a 200-day moving average price of $16.26. The stock’s market capitalization is $739.38 million. Coherus BioSciences has a 1-year low of $10.80 and a 1-year high of $31.48.

Coherus BioSciences (NASDAQ:CHRS) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($1.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.29) by $0.21. Coherus BioSciences had a negative net margin of 73.89% and a negative return on equity of 307.41%. The company had revenue of $1.40 million during the quarter. Equities research analysts predict that Coherus BioSciences will post ($5.13) earnings per share for the current fiscal year.

In other news, insider Alan C. Herman sold 17,535 shares of Coherus BioSciences stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $15.02, for a total transaction of $263,375.70. Following the completion of the sale, the insider now directly owns 49,651 shares of the company’s stock, valued at approximately $745,758.02. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 26.28% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its position in shares of Coherus BioSciences by 0.3% during the 2nd quarter. FMR LLC now owns 7,693,124 shares of the biotechnology company’s stock worth $110,396,000 after purchasing an additional 21,143 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Coherus BioSciences by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 2,255,467 shares of the biotechnology company’s stock worth $32,367,000 after purchasing an additional 46,223 shares during the last quarter. State Street Corp lifted its position in shares of Coherus BioSciences by 26.8% during the 2nd quarter. State Street Corp now owns 1,416,572 shares of the biotechnology company’s stock worth $20,329,000 after purchasing an additional 298,986 shares during the last quarter. UBS Asset Management Americas Inc. lifted its position in shares of Coherus BioSciences by 54.5% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 1,391,216 shares of the biotechnology company’s stock worth $19,964,000 after purchasing an additional 490,899 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Coherus BioSciences by 2.6% during the 1st quarter. Wellington Management Group LLP now owns 1,268,479 shares of the biotechnology company’s stock worth $26,829,000 after purchasing an additional 32,150 shares during the last quarter. 78.19% of the stock is owned by institutional investors and hedge funds.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Analyst Recommendations for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.